SCHEMBL4043451

SCHEMBL4043451

COc1cccc(-n2nc(Nc3ccc(Oc4ccccc4)cc3)nc2N)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.63
ALDH1A1 P00352 1/20 0.52
IMPDH2 P12268 1/20 0.51
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
KIT P10721 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
MAPT P10636 1/20 0.46
HSD17B10 Q99714 1/20 0.46
AXL P30530 2/20 0.45
BACE1 P56817 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
SCN5A Q14524 1/20 0.43
SCN9A Q15858 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038418 0.93 FLT3 (0.65) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4038398 0.91 FLT3 (0.62) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4039312 0.89 FLT3 (0.62) FLT3ALDH1A1IMPDH2KITAXL
SCHEMBL4040002 0.85 FLT3 (0.67) FLT3ALDH1A1IMPDH2JAK2SMN1; SMN2
SCHEMBL4042636 0.84 FLT3 (0.80) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4039213 0.83 FLT3 (0.64) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4037275 0.81 FLT3 (0.56) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4036725 0.81 FLT3 (0.62) FLT3JAK2KITIRAK4MAPT
SCHEMBL4775480 0.80 BACE1 (0.73) AXLBACE1
SCHEMBL12779188 0.79 MAPK1 (0.53) FLT3ALDH1A1MAPTHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885ALDH1A1 3235/4885IMPDH2 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.